Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppression. Several strategies have been developed to overcome such limitations, including the use of immunostimulatory adjuvants, the co-treatment with cytotoxic anticancer therapies that enable the coordinated release of damage-associated molecular patterns, and the concomitant blockade of immune checkpoints. Personalized peptide-based vaccines are also being explored for therapeutic activity in the clinic. Here, we review recent preclinical and clinical progress in the use of peptide-based vaccines as anticancer therapeutics.
Introduction
Immunotherapy constitutes an efficient way to treat cancer based on the (re)activation of the natural capacity of the host immune system to recognize malignant cells as "non-self" and hence eliminate them. [1] [2] [3] [4] [5] [6] [7] Over the past years, a panoply of different approaches has been developed or repurposed to (re)initiate anticancer immunity, [8] [9] [10] [11] [12] including immune checkpoint blockers targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) and its main ligand CD274 (best known as PD-L1);
13-19 chemotherapy with immunogenic cell death (ICD) inducers, 20-25 recombinant cytokines, 26,27 monoclonal antibodies (mAbs) that activate co-activatory receptors, 28, 29 adoptively transferred T cells engineered to express a tumorspecific chimeric antigen receptor (CAR), [30] [31] [32] [33] [34] [35] [36] as well as multiple small molecules targeting distinct immunosuppressive pathways operating within the tumor microenvironment. [37] [38] [39] [40] Although some of these strategies have demonstrated unprecedented activity in patients with advanced tumors refractory to several lines of conventional treatment, 41 the fraction of individuals responding to single-agent immunotherapy is generally low, [42] [43] [44] [45] arguably with the sole exception of CAR-expressing T cells, which have been associated with >70% overall response rate in pediatric patients with B-cell acute lymphocytic leukemia (ALL).
46-48 Thus, immunotherapy is most often implemented as part of combinatorial regimens involving other treatment modalities such as surgery, chemotherapy and/or radiation therapy (RT). [49] [50] [51] [52] [53] [54] Importantly, all tumors express proteins that differ in quality or quantity from their germline-encoded counterparts, owing to genetic and/or epigenetic alterations that accumulate as the disease progress. [55] [56] [57] Once processed by the proteasome, these proteins can give rise to antigens that are not covered by central or peripheral tolerance and hence can be productively presented by dendritic cells (DCs) to T lymphocytes to drive an adaptive immune response.
55,58-64 Such antigens are commonly known as "tumor-associated antigens" (TAAs). 55, 65 A large list of TAAs with sequences that bind human MHC Class I or II molecules and the TCR can be found at http://cvc.dfci.harvard.edu/tadb (the Tantigen database). One specific class of TAAs is constituted by socalled "tumor neoantigens" (TNAs). [66] [67] [68] [69] [70] [71] At odds with other variants of TAAs including oncofetal antigens and cancertestis antigens, which can be expressed by healthy tissues (at least at some stage of development), 37, [72] [73] [74] [75] TNAs are produced as a consequence of genetic alterations that are highly specific for the tumor, or even portions thereof. [76] [77] [78] Similarly, TNAs that are fully tumor-specific occur upon the rearrangement of immunoglobulin-coding genes in clonal B-cell malignancies. 79 Finally, tumor-specific TAAs can be generated as a consequence of viral transformation, 80 as in the case of human papillomavirus type 16 (HPV-16)-driven oral and cervical tumors. 81, 82 TAAs in all their forms have been harnessed for the development of tumor-specific vaccines for therapeutic applications, [83] [84] [85] [86] including formulations based on recombinant or purified polypeptides generally administered together with an immunological adjuvant in suitable vehicles. [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] However, TAAs often display limited antigenicity (reflecting the fact that they generally resemble self-antigens that are covered by tolerance). [104] [105] [106] Moreover, tumors emerge and evolve as they become able to escape natural immunosurveillance, [107] [108] [109] [110] either because the lose expression of potentially antigenic proteins, and/or because they establish an immunosuppressive milieu that enforces local tolerance. [111] [112] [113] [114] [115] [116] Thus, besides a few exceptions and despite promising preclinical findings, 117 multiple studies demonstrate that peptide-based vaccines employed as standalone adjuvanted interventions have limited clinical activity (although they generally cause some signs of tumor-targeting immunity). [118] [119] [120] [121] In line with this notion, no peptide-based vaccines are currently approved by the US Food and Drug Administration (FDA) or equivalent agencies worldwide for use in cancer patients are therapeutic measures (source http://www.fda.gov). However, on 2017, July 10th, the FDA has granted Orphan Drug Designation (ODD), which is designed to encourage the preparation of new molecules for indications affecting fewer than 200,000 people in the US, to DSP-7888, a new peptide-based vaccine targeting Wilms tumor 1 (WT1). 122 Of note, Gardasil®, Gardasil 9® and Cervarix® are licensed for use in healthy women as prophylactic vaccines against multiple variants of HPV which are associated with the development of cervical carcinomas and anal cancers. [123] [124] [125] [126] [127] [128] That said, these agents technically represent antiviral vaccines and have limited activity against established HPV-driven tumors. 99, [129] [130] [131] Recent attempts to improve the efficacy of peptide-based vaccines converged on the development of combinatorial immunotherapeutic regimens that simultaneously drive TAA-specific immunity as they inhibit local immunosuppression. 132 Considerable attention in this sense has been attracted by immune checkpoint blockers, 86, [133] [134] [135] [136] despite initial setbacks linked to the lack of added therapeutic value when ipilimumab (an FDA-approved mAb targeting CTLA) was combined with a peptide vaccine targeting premelanosome protein (PMEL, also known as gp100) in melanoma patients. 137 Along the lines of previous Trial Watches from our series, 138, 139 here we summarize recent clinical advances in the development of peptide-based therapeutic vaccines for cancer therapy.
Literature update

Clinical literature
Since the publication of the last Trial Watch dealing with this topic (April 2015), 118 the results of no less than 20 clinical trials testing peptide-based vaccination as a therapeutic approach in cancer patients have reported in the peer-reviewed literature (source https://www.ncbi.nlm.nih. gov/pubmed and http://meetinglibrary.asco.org/abstracts). Most of these trials were Phase I or II studies designed for testing the safety and immunogenicity (as opposed to the therapeutic efficacy) of TAA-derived peptides. Peptidebased vaccination was employed as a standalone adjuvanted intervention, [140] [141] [142] [143] [144] [145] [146] or combined with chemotherapy [147] [148] [149] radiation therapy 147, 150 or other forms of treatment including other immunotherapies. 148, 149, [151] [152] [153] [154] [155] [156] [157] [158] These studies enrolled patients with hematological malignancies, 151, 159 brain tumors, 152, 153 non-small cell lung carcinoma (NSCLC), 140, 147, 160 breast cancer, 141, 148, 161 , prostate carcinoma, 142 ,154 melanoma, [144] [145] [146] [155] [156] [157] [158] 162 . ovarian cancer. 149 , cervical cancer, 163 hepatocellular carcinoma 164 and biliary tract cancer 165 . The TAAs harnessed for the construction of peptide-based vaccines in these studies included the cancer/testis antigen 1B (CTAG1B; best known as NY-ESO-1), 144 MAGE family member A3 (MAGEA3), 140, 146, 147 TTK protein kinase (TTK), 158 WT1, 151,166 baculoviral IAP repeat containing 5 (BIRC5; best known as survivin), 149 mutant epidermal growth factor receptor (EGFRvIII), 153 erb-b2 receptor tyrosine kinase 2 (ERBB2; best known as HER2), 148 indoleamine 2,3 dioxygenase 1 (IDO1), 157 TCR gamma alternative reading frame protein (TARP), 154 and multiple glioma-associated antigens. 152 Most often, peptidebased vaccines were well tolerated and no severe side effects were reported. Mild side effects were sporadic and included flu-like symptoms, fatigue and minor reactions at the injection site. Immunes responses driven by vaccination were documented in a variety of studies based on (1) interferon gamma (IFNG) production by T cells with enzyme-linked immunospot (ELISPOT) assays, 142, 151, 152, 154, 155 146 Thus, vaccination strategies targeting MAGEA3 appear to be best suited for the treatment of advanced unresectable (rather than resectable) or chemotherapy-ineligible NSCLCs.
Weller et al.
(from University Hospital of Zurich, Zurich, Switzerland) designed a randomized double-blind Phase III clinical trial to investigate the efficacy of rindopepimut, a peptide-based vaccine targeting EGFRvIII, in patients with newly diagnosed glioblastoma receiving or not conventional temozolomide-based chemotherapy. No difference in OS was documented between group, calling for a re-evaluation of the therapeutic approach. 153 Taken together, these clinical findings corroborate the notion that TAA-targeting peptide-based vaccines are well tolerated by cancer patients and initiate tumor-targeting immune responses (at least to some degree), but mediate limited therapeutic effects when employed as standalone adjuvanted interventions. The promising results obtained in melanoma patients by Ott and collaborators with a TNAtargeting approach 168 will have to be validated in larger controlled, randomized Phase II studies. Moreover, the efficacy of TNA-based PPV (employed alone or combined with immune checkpoint blockers) against tumors with a relatively low mutational burden 77, 169, 170 remains to be established.
Preclinical literature
Among recent preclinical studies dealing with peptide-based anticancer vaccines, we found of particular interest the works of: (1) Zhu and colleagues (from the National Institutes of Health, Bethesda, MD, USA), who developed self-assembling albumin-vaccine nanocomplexes that reportedly enable superior delivery and mediated robust therapeutic effect against transplantable tumors growing in immunocompetent mice, especially when combined with immune checkpoint blockers and chemotherapy; 94 172 (4) Petrizzu and collaborators (from the Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy), who showed that metronomic chemotherapy plus a PD-1-targeting immune checkpoint blocker are highly efficient in potentiating the antitumor effects of a multi-peptide vaccine in a mouse model of melanoma; 173 and (5) Tanaka and co-workers (from the Yamaguchi University, Ube, Japan), who demonstrated that miR-125b-1 and miR-378a expression levels may be harnessed to predict the efficacy of peptide-based vaccination against colorectal carcinoma. 99 that potentially compromise therapeutic efficacy when peptide-based vaccines and immune checkpoint blockers 134 or chemotherapy 175 are combined. These data suggest that additional work is required to fully decode the pharmacological and immunological interactions between peptide-based anticancer vaccines and other treatment modalities.
Ongoing clinical trials
Since the last Trial Watch dealing with peptide-based vaccines for oncological indications has been published (April 2015), 118 no less than 66 clinical trials have been initiated to test this immunotherapeutic modality in cancer patients (source www.clinicaltrials.gov) ( Table 1) . A large majority of these studies involve either short TAAderived peptides that can directly bind to MHC Class I or II molecules expressed by antigen-presenting cells 176 (42 studies), or SLPs that are processed intracellularly and then loaded on MHC Class I or II molecules 172, 177, 178 (22 studies), most often in combination with immunological adjuvants [179] [180] [181] [182] like montanide ISA-51 (water-in-oil emulsion) 181, 183 Hiltonol® (poly-L-lysine in carboxymethylcellulose, a TLR3 ligand) 184 and GM-CSF. 183, [185] [186] [187] In several instances, vaccination is further combined with standard treatment regimens including conventional chemotherapy, 117, [188] [189] [190] [191] radiation therapy, 52, [192] [193] [194] [195] and targeted anticancer agents, [196] [197] [198] [199] or with various immunotherapeutic interventions. [200] [201] [202] [203] [204] [205] The latter include (1) immune checkpoint blockers such as the anti-PD-1 mAbs pembrolizumab and nivolumab, [206] [207] [208] the anti-PD-L1 mAbs durvalumab and atezolizumab, [209] [210] [211] and the anti-CTLA4 mAb ipilimumab; 137, 186, [212] [213] [214] [215] (2) immunostimulatory antibodies such as utomilumab, which stimulates TNF receptor superfamily member 9 (TNFRSF9; best known as 4-1BB or CD137) signaling, 28, [216] [217] [218] or the CD27 agonist varlilumab; 28,216,219,220 and immunomodulatory agents such as lenalidomide. [221] [222] [223] [224] In line with preclinical and clinical data demonstrating that multi-epitope vaccines are generally more powerful than their singleepitope counterparts, 117,225 the most common vaccination strategy employed by these studies consists in targeting simultaneously multiple TAAs (20 studies). Alongside, 15 studies are investigating the safety and efficacy of PPV, often consisting of MHC-matched peptides chosen from the immune repertoire of the patient before treatment. 226 Finally, several studies aim at testing the safety and therapeutic potential of peptide-based vaccines targeting one single TAA including not only viral antigens like HPV p16, E6 and E7, [227] [228] [229] but also shared TAAs like HER2, NY-ESO-1, survivin and telomerase reverse transcriptase (TERT), 161, as well as TAAs involved in the establishment of immunosuppression, such as PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1). [253] [254] [255] [256] Taken together, these clinical trials enroll patients with a wide panel of neoplasms, including (but not limited to) glioblastoma, glioma and other brain tumors (NCT02722512; NCT02924038; NCT03068832; NCT03299309; NCT02750891; NCT03149003; NCT02287428; NCT02455557; NCT02754362; NCT02864368; NCT03223103; NCT03422094; NCT02358187; NCT02454634; NCT02960230), breast carcinoma (NCT02276300; NCT025932 27; NCT02636582; NCT03012100; NCT02826434; NCT0336 2060), hematological malignancies (NCT02240537; NCT02802943; NCT03219450; NCT02396134; NCT02750995; NCT03121677; NCT03361852; NCT03381768; NCT02436252), melanoma (NCT02320305; NCT02334735; NCT02382549; NCT02385669; NCT02425306; NCT02515227; NCT02696356; NCT03047928), ovarian carcinoma (NCT02764333; NCT02978 222; NCT02737787; NCT02933073) and prostate cancer (NCT03412786; NCT02293707; NCT02452307; NCT03199872).
Although final statistical assessments are still awaited, preliminary results from 8 clinical trials that have been completed or terminated since the publication of our last Trial Watch dealing with peptide-based anticancer vaccines (April 2015) 118 have become available (source www.clinicaltrials.gov). NCT01423760, an open-label, common safety follow-up trial testing a MUC1-targeting vaccine (tecemotide) in patients with myeloma and NSCLC has been terminated prematurely as per decision of the sponsor. Out of 27 patients enrolled in the study, 20 were evaluable for toxicity, which was more severe in the NSCLC arm. NCT00409188, a Phase III study testing tecemotide in combination with single low-dose cyclophosphamide in subjects with NSCLC has been completed. Primary endpoint was not met, but notable survival benefits were achieved in patients treated with concurrent chemoradiotherapy, 257 NCT01507103, a Phase II study testing the therapeutic profile of tecemotide combined with cyclophosphamide or cyclophosphamide plus chemoradiation in subjects with rectal cancer, has been completed. No difference in incidence and severity of adverse events were noted. NCT01380145, an open-label, single-arm, pilot study of recombinant MAGEA3 adjuvanted with AS15 258 as consolidation for multiple myeloma patients undergoing autologous stem cell transplantation, has been completed. Treatment was immunologically active, but grade 3-4 adverse events were experienced by 12 of the 13 participants in the study. One year after treatment there were 4 patients in stringent complete response (CR), 1 in CR, 4 in very good partial response (PR) and 4 Abbreviations. CMV, cytomegalovirus; CRC, colorectal carcinoma; DC, dendritic cell; HCC, hepatocellular carcinoma; HPV, human papillomavirus; MDS, myelodysplastic syndrome; n.a., not available; NSCLC, non-small cell lung carcinoma; PPV, personalized peptide vaccination, SLP, synthetic long peptide; TAA, tumor-associated antigen.
with progressive disease. NCT00849875, a Phase II study testing MUC1-targeting vaccination plus dacarbazine in melanoma patients, has been terminated due to lack of scientific justification to continue collect data. Of 48 participants analyzed, 10 had serious adverse events. Seroconversion occurred in all patients, but clinical activity was limited to 1 CRs and 3 PRs. NCT00706992, a Phase 2 trial testing a peptide-based vaccine specific for melan-A (MLANA; also known as MART-1) together with MART-1-targeting lymphocytes in high-risk melanoma patients, has been terminated owing to low accrual. No robust immunological responses were documented among 40 evaluable patients. Adverse events were common, but never serious. NCT01322815, a Phase II study assessing the therapeutic profile of a peptide-based vaccine targeting mutant KRAS combined with standard chemotherapy or a mAb specific for vascular endothelial growth factor A (VEGFA) 259 in patients with colorectal carcinoma, has been terminated owing to poor accrual rate. Four months after the initiation of treatment, 50% of patients were alive and free of progression, but 2 patients receiving GI-4000 plus chemotherapy suffered from serious adverse effects. NCT00643097, a Phase I-II trial investigating the safety and preliminary therapeutic profile of an EGFRvIIIdirected vaccine adjuvanted with GM-CSF in patients with glioblastoma, has been completed. Of 30 participants evaluable for the immunogenicity of the vaccine, 10 presented robust immune responses, median progression-free survival was between 11.6 and 14.2 months. NCT01307618, a Phase II study testing a multi-epitope peptide-based vaccine in combination with a CD25-specific antibody (daclizumab) ± recombinant metastatic interleukin 12 (IL12) in patients with metastatic melanoma, was terminated due to lack of efficacy.
Concluding remarks
In the past few years, tremendous progress has been made towards understanding the molecular and cellular pathways whereby the immune system can recognize and eradicate premalignant and malignant cells naturally as well as in response to some treatment regimens.
9,20,21,260 Such knowledge has been instrumental for the development of a wide panel of therapeutic interventions that specifically aim at (re)establishing anticancer immunosurveillance (rather than merely causing the death of malignant cells), including peptide-based vaccination.
8, 105, 176, [261] [262] [263] [264] Unfortunately, it has soon become clear that the majority of immunotherapies developed so far is poorly active when employed as standalone therapeutic intervention, largely reflecting (1) natural and treatment-driven immunoediting, resulting in the selection of poorly immunogenic cancer cell populations; 115, 265, 266 and (2) the robust immunosuppression established by malignant cells, both locally and systemically. [267] [268] [269] In line with this notion, the vast majority of peptide-based vaccines tested in the clinic so far mediated limited, if any, therapeutic activity, despite being able to elicit tumor-targeting immune responses, at least to some degree. 118 The field is therefore moving along three non-mutually exclusive directions: (1) combining peptidebased vaccination with additional forms of (immuno)therapy, with the specific aim of reverting immunosuppression and enabling therapeutically relevant immune responses, [270] [271] [272] (2) targeting private antigenic epitopes that originate from mutations affecting only malignant cells (or sub-populations thereof), with PPV, 167, [272] [273] [274] [275] and (3) identifying specific patient populations that may obtain clinical benefit from the use of peptide-based vaccination. 174, 254 Although the feasibility of PPV on a large scale remains unclear, we surmise combining some variants of peptide-based vaccination with potent immunostimulatory agents including immune checkpoint blockers and oncolytic viruses may be the key to unlock the true potential of this hitherto unrealized therapeutic modality. 
